2018
PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC).
Bordeaux J, Dakappagari N, Pennell N, Stevenson J, Khunger M, Vaupel C, Schalper K, Rimm D, Velcheti V. PD-1/PD-L1 interaction and CD25/FOXP3+ t cells to predict survival benefit from adjuvant chemotherapy in early stage non–small-cell lung cancer (ES-NSCLC). Journal Of Clinical Oncology 2018, 36: 12059-12059. DOI: 10.1200/jco.2018.36.15_suppl.12059.Peer-Reviewed Original Research
2017
MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung Cancer
Velcheti V, Bordeaux J, Dakappagari N, Pennell N, Stevenson J, Khunger M, Kim J, Schalper K, Rimm D. MA 13.03 Quantitative Spatial Profiling of PD-1/PD-L1 Interaction Predicts Response to Adjuvant Chemotherapy Non–Small-Cell Lung Cancer. Journal Of Thoracic Oncology 2017, 12: s1852. DOI: 10.1016/j.jtho.2017.09.562.Peer-Reviewed Original ResearchQuantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM).
Johnson D, Bordeaux J, Kim J, Vaupel C, Rimm D, Ho T, Joseph R, Daud A, Conry R, Gaughan E, Dimou A, Balko J, Smithy J, Witte J, McKee S, Dominiak N, Dabbas B, Hall J, Dakappagari N. Quantitative spatial profiling of PD-1/PD-L1 interaction and HLA-DR/IDO1 to predict outcomes to anti-PD-1 in metastatic melanoma (MM). Journal Of Clinical Oncology 2017, 35: 9517-9517. DOI: 10.1200/jco.2017.35.15_suppl.9517.Peer-Reviewed Original ResearchHLA-DRValidation cohortMetastatic melanomaPD-1/PD-L1Anti-PD-1 therapyPD-1/L1Pre-treatment tumor biopsiesPD-1/PD-L1 interactionPD-1 monotherapyPD-L1 expressionProgression-free survivalBiomarkers of responseFuture clinical trialsMultiple immune markersPD-L1 interactionImmune suppression mechanismsPrior therapyFree survivalDurable responsesOverall survivalPD-L1Immune markersClinical trialsTreatment responseTumor biopsies